Myelodysplastic Syndromes
June 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Authors:Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ
Institution:Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. Beijing, China. huangxiaojun@bjmu.edu.cn. huangxiaojun@bjmu.edu.cn. China. huangxiaojun@bjmu.edu.cn.
Journal:Ann Hematol. 2017 May;96(5):829-838. doi: 10.1007/s00277-017-2960-7. Epub 2017 Mar 11.

2:Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Authors:Stahl M, Zeidan AM
Institution:a Section of Hematology, Department of Internal Medicine, Section of Hematology, Yale University and the Yale Comprehensive Cancer Center , Yale University School of Medicine , New Haven , CT , USA. Yale University and the Yale Comprehensive Cancer Center , Yale University School of Medicine , New Haven , CT , USA.
Journal:Expert Rev Hematol. 2017 Apr;10(4):345-364. doi: 10.1080/17474086.2017.1297704. Epub 2017 Mar 9.

3:Myelodysplastic Syndromes: Updates and Nuances.
Authors:Dao KT
Institution:Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Mail Code: UHN73C, 3181 South West Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: daok@ohsu.edu.
Journal:Med Clin North Am. 2017 Mar;101(2):333-350. doi: 10.1016/j.mcna.2016.09.006.

4:Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Authors:Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Maryland. Hospital, Detroit, Michigan. Houston, Texas.
Journal:Cancer. 2017 May 15;123(6):994-1002. doi: 10.1002/cncr.30533. Epub 2017 Jan 17.

5:Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.
Authors:Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D
Institution:Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: gorti@vebron.net. University Hospital, Barcelona, Spain. University Hospital, Barcelona, Spain. University Hospital, Barcelona, Spain. University Hospital, Barcelona, Spain. University Hospital, Barcelona, Spain.
Journal:Exp Hematol. 2017 Apr;48:1-11. doi: 10.1016/j.exphem.2016.12.004. Epub 2016 Dec 24.

6:TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Authors:Chang CK, Zhao YS, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu LY, Su JY, Song LX, Xiao C, Li X
Institution:Department of Haematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China. People's Hospital, Shanghai, China.
Journal:Br J Haematol. 2017 Feb;176(4):600-608. doi: 10.1111/bjh.14455. Epub 2016 Dec 16.

7:Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Authors:Imran F, Phatak P
Institution:a Lipson Cancer and Blood Center , Rochester Regional Health System , Rochester , NY , USA. NY , USA.
Journal:Expert Rev Hematol. 2017 Jan;10(1):53-64. doi: 10.1080/17474086.2017.1268910. Epub 2016 Dec 16.

8:Asthma and risk of myelodysplastic syndromes: a population-based cohort study.
Authors:Frederiksen H, Farkas DK, Horvath-Puho E, Norgaard JM, Norgaard M, Sorensen HT
Institution:Department of Haematology, Odense University Hospital, Odense, Denmark.
Journal:Br J Cancer. 2017 Jan 3;116(1):100-102. doi: 10.1038/bjc.2016.389. Epub 2016 Nov 29.

9:Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
Authors:Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V
Institution:Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Departamento de Hematologia, CIPM, Rua Prof. Lima Basto, 1099-023, Lisbon, Portugal. Electronic address: amalmeida@ipolisboa.min-saude.pt. France. Dresden, Dresden, Germany.
Journal:Leuk Res. 2017 Jan;52:50-57. doi: 10.1016/j.leukres.2016.11.008. Epub 2016 Nov 13.

10:Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes.
Authors:Deshet-Unger N, Oster HS, Prutchi-Sagiv S, Maaravi N, Golishevski N, Neumann D, Mittelman M
Institution:Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. Sackler Faculty of Medicine, Tel Aviv University, Israel. Aviv University, Tel Aviv 69978, Israel. Sackler Faculty of Medicine, Tel Aviv University, Israel. Sackler Faculty of Medicine, Tel Aviv University, Israel. Aviv University, Tel Aviv 69978, Israel. Sackler Faculty of Medicine, Tel Aviv University, Israel. Electronic address: moshemt@tlvmc.gov.il.
Journal:Leuk Res. 2017 Jan;52:20-27. doi: 10.1016/j.leukres.2016.11.002. Epub 2016 Nov 2.

11:The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
Authors:Sperling AS, Gibson CJ, Ebert BL
Institution:Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. Boston, Massachusetts 02115, USA. Women's Hospital, Boston, Massachusetts 02115, USA. Boston, Massachusetts 02115, USA. Women's Hospital, Boston, Massachusetts 02115, USA. Boston, Massachusetts 02115, USA.
Journal:Nat Rev Cancer. 2017 Jan;17(1):5-19. doi: 10.1038/nrc.2016.112. Epub 2016 Nov 11.

12:A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
Authors:Pappa V, Anagnostopoulos A, Bouronikou E, Briasoulis E, Kotsianidis I, Pagoni M, Zikos P, Tsionos K, Viniou N, Meletis J, Papadaki H, Kioumi A, Galanopoulos A, Vervessou EC, Poulakidas E, Karmas P, Karvounis K, Symeonidis A
Institution:University General Hospital 'Attikon', 1, Rimini Str, Chaidari, 12462, Athens, Greece. vas_pappa@yahoo.com. Greece. Xanthi, Greece. 56429, Thessaloniki, Greece. Athens, Greece.
Journal:Int J Hematol. 2017 Feb;105(2):184-195. doi: 10.1007/s12185-016-2115-y. Epub 2016 Nov 4.

13:A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Authors:Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD
Institution:Department of Medicine, Yale University, New Haven, CT, USA. Cleveland, OH, USA.
Journal:Br J Haematol. 2017 Jan;176(2):241-247. doi: 10.1111/bjh.14407. Epub 2016 Oct 28.

14:Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
Authors:Del Corso L, Biale L, Parodi EL, Russo R, Filiberti R, Arboscello E
Institution:Internal Medicine, Department of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. Corso Bramante 88, 10126, Turin, Italy. San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. Genoa, Italy. Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. eleonora.arboscello@alice.it.
Journal:Int J Clin Oncol. 2017 Apr;22(2):380-386. doi: 10.1007/s10147-016-1042-5. Epub 2016 Oct 22.

15:Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Authors:Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Cancer Center, Houston, Texas. Houston, Texas. Houston, Texas.
Journal:Cancer. 2017 Feb 15;123(4):629-637. doi: 10.1002/cncr.30383. Epub 2016 Oct 14.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: June 23, 2017
169 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS92540919

Coupon Expires: August 25, 2017



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.